Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 436-441

  D'Amico, Anthony V ^a   Chen, Ming Hui ^b   Oh Ung, Jean ^a   Renshaw, Andrew A ^a   Cote, Kerri ^a   Loffredo, Marian ^a   Richie, Jerome P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Outcome; Presentation; Prostate specific antigen; Prostatic neoplasms; Radical prostatectomy; Radiotherapy

Indexed keywords

ANTIGENS; BIOPSY; PATHOLOGY; RADIOTHERAPY; SURGERY;

RADICAL PROSTATECTOMY (RP);

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0036803132     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02940-1     Document Type: Article

References (20)

1. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:1993;948-954.
2. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer Results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
3. Stamey T.A., Donaldson A.N., Yemotot C.E., et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy Epidemiologic significance of annual changes . J Urol. 160:1998;2412-2417.
4. Farkas A., Schneider D., Perrotti M., et al. National trends in the epidemiology of prostate cancer, 1973 to 1994 Evidence for the effectiveness of prostate-specific antigen screening . Urology. 52:1998;444-448.
5. Smith D.S., Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 152:1994;1732-1736.
6. Humphrey P.A., Keetch D.W., Smith D.S., et al. Prospective characterization of pathologic features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol. 155:1996;816-820.
7. Han M., Partin A.W., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 166:2001;416-419.
8. Buchsbaum J.C., Elshaikh M.A., Kupelian P.A., et al. Year of treatment is an independent predictor of outcome in patients with localized prostate cancer treated with definitive radiotherapy. [Abstract] Int J Radiat Oncol Biol Phys. 51:2001;169.
9. Cagiannos I., Karakiewicz P., Graefen M., et al. Year of radical prostatectomy is an independent predictor of outcome in prostate cancer. [Abstract] J Urol. 165:2001;65.
10. The Veterans Administration Cooperative Urological Research Group, Gleason D.F. Histologic grading and staging of prostatic carcinoma. Tannenbaum M., Urologic pathology. 1977;171-187 Lea & Febiger, Philadelphia.
11. Lee C.T., Oesterling J.E. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am. 24:1997;389-394.
12. Beahrs O.H., Henson D.E., Hutter R.V.P., The American Joint Committee on Cancer . Manual for staging cancer. 4th ed. 1992;JB Lippincott, Philadelphia.
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. The clinical utility of the percent of positive prostate biopsies in defining biochemical outcome following radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 18:2000;1164-1172.
14. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 49:2001;679-684.
15. The American Society for Therapeutic Radiology and Oncology Consensus Panel, Cox J.D. Consensus Statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
16. Simultaneous inferences, and other topics in regression analysis -1. Neter J., Wasserman W., Kutner M., Applied linear regression models. 1st ed. 1983;150-153 Richard D. Irwin, Homewood, IL.
17. Bolla M., Gonsalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
18. Gerber R.L., Smith A.R., Owen J., et al. Patterns of care survey results Treatment planning for carcinoma of the prostate . Int J Radiat Oncol Biol Phys. 33:1995;803-808.
19. Walsh P.C. Radical retropubic prostatectomy with reduced morbidity An anatomic approach . NCI Monogr. 7:1988;133-137.
20. Lee W.R., Hanlon A.L., Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer The relationship between nadir level and disease free survival . J Urol. 156:1996;450-453.